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Abstract
The attenuation of myxoma virus (MYXV) following its introduction as a biological control into the European rabbit
populations of Australia and Europe is the canonical study of the evolution of virulence. However, the evolutionary genetics
of this profound change in host-pathogen relationship is unknown. We describe the genome-scale evolution of MYXV
covering a range of virulence grades sampled over 49 years from the parallel Australian and European epidemics, including
the high-virulence progenitor strains released in the early 1950s. MYXV evolved rapidly over the sampling period, exhibiting
one of the highest nucleotide substitution rates ever reported for a double-stranded DNA virus, and indicative of a relatively
high mutation rate and/or a continually changing selective environment. Our comparative sequence data reveal that
changes in virulence involved multiple genes, likely losses of gene function due to insertion-deletion events, and no
mutations common to specific virulence grades. Hence, despite the similarity in selection pressures there are multiple
genetic routes to attain either highly virulent or attenuated phenotypes in MYXV, resulting in convergence for phenotype
but not genotype.
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Introduction
The classic model of pathogen evolution following a species
jump is the introduction of the lethal myxoma virus (Poxviridae,
genus Leporipoxvirus) into the European rabbit (Oryctolagus cuniculus)
populations of Australia as a biological control [1]. MYXV causes
a largely innocuous cutaneous fibroma in its natural host, the
South American tapeti (Sylvilagus brasiliensis). However, in Europe-
an rabbits the same virus causes the systemic lethal disease
myxomatosis. A strain of this highly virulent virus – Standard
Laboratory Strain (SLS) – was successfully introduced into wild
European rabbits in Australia in 1950 and over the next five years
spread across the entire continental range of the rabbit. With
outstanding foresight, Fenner and colleagues tracked the pheno-
typic evolution of virulence in the Australian epidemic by testing
the lethality of viral isolates taken from the field over the
subsequent decades in laboratory rabbits (of the same species as
those infected in the wild).
SLS had a case fatality rate (CFR) estimated at 99.8% [1].
However, within two years of the introduction of SLS, and despite
the ongoing release of virulent viruses, slightly attenuated MYXV
strains came to dominate field populations. Although they still
killed 90–99% of infected rabbits, these lower virulence strains
allowed infected rabbits to survive for longer, increasing the
probability of transmission from skin lesions by mosquito vectors
[2,3]. MYXV virus does not replicate in the vector [2,4], so that
transmission is dependent on high titres in cutaneous lesions ($107
infectious particles/g) and the duration of survival of the infected
rabbit. Highly attenuated viruses could be quickly controlled by
the rabbit immune system and so tended to have relatively low
transmissibility [2]. For the next 30 years the majority of MYXV
were of intermediate virulence with CFRs of 70–95% in
laboratory rabbits [5]. At the same time, natural selection acted
on the wild rabbit population, resulting in the emergence of
animals resistant to myxomatosis [6,7], likely through an enhanced
innate immune response [8,9]. This effectively reduced the
virulence of field strains of MYXV in wild compared to laboratory
rabbits. Uniquely, this evolutionary experiment was repeated in
Europe following the release of a separate South American strain
of MYXV (Lausanne strain; Lu) into France in 1952. The
evolutionary outcomes were strikingly similar to those in Australia,
with the emergence of attenuated virus strains and selection for
resistant rabbits [1].
These remarkable natural experiments in biological control
have become the bedrock of the mathematical theory of virulence
evolution [10–13], revealing much about the relationship between
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virulence and transmissibility. The hypothesis is that a reduction in
virulence was selectively favoured because, by killing hosts so
rapidly, highly virulent viruses had shorter infectious periods and
hence lower fitness. The emergence of attenuated viruses may also
have aided the selection of resistant rabbits [1,7], in turn driving
the evolution of more virulent MYXV in subsequent decades in an
archetypal host-pathogen arms race [14,15].
Despite the canonical position of MYXV in studies of virulence
evolution, the critical body of work occurred in the pre-genomic
era. Today, we know that at least 20 genes encoding proteins with
immune evasion or host range functions have a demonstrated role
in MYXV virulence based on gene knock-out studies, and a
further 20 proteins are predicted to have similar functions [16,17].
However, both the pattern of molecular evolution and the genetic
basis to the changes in virulence in both the Australian and
European epidemics is largely unknown. Here we use comparative
genomics to illuminate these uniquely important evolutionary
events.
Results
Evolutionary history and dynamics of MYXV
The genome of the Lu strain of MYXV comprises 161.8 kb of
double-strand (ds) DNA with terminal inverted repeats (TIRs) of
11,577 bp. MYXV contains 158 unique open reading frames, 12
of which are duplicated in the TIRs. The central region of the
genome encodes genes involved in viral replication that are
strongly conserved among poxviruses. Genes located towards the
termini and within the TIRs are less conserved, have roles in
immune evasion and host-range, and have been shown to be
critical for virulence in European rabbits [16,17].
We obtained complete or near complete genome sequences of
22 isolates of MYXV (Table 1), with the Lu strain [16] also
sequenced as a quality control. These data were combined with
the published sequence of a single Spanish isolate (MYXV/6918)
sampled in 1995 [18]. A maximum likelihood phylogenetic
analysis of these 24 complete MYXV genomes revealed a division
between those viruses released in Australia (SLS progenitor) and
Europe (Lu progenitor), a strong temporal structure, such that
those viruses sampled earlier in time (1940s and 1950s) fall closer
to the root of the tree, and frequent changes in virulence grade
over the sampling period (Figure 1a).
A parsimony analysis reconstructed 482 mutations across the
MYXV phylogeny (mean pairwise distance among iso-
lates = 0.05%), of which 207 were synonymous, 249 nonsynon-
ymous, and 26 occurred in non-coding or intergenic regions.
These data were also characterized by a high consistency index
(0.89) indicative of limited homoplasy, and no recombination was
observed. A Bayesian Markov chain Monte Carlo analysis [19]
recovered a mean evolutionary rate of 9.661026 nucleotide
substitutions per site, per year (95% HPD values, 8.3–10.961026
subs/site/year) under a strict molecular clock, with almost
identical estimates obtained using a relaxed clock. Because both
clock models have essentially identical likelihoods, and the
coefficient of rate variation includes zero, we conclude that
MYXV has evolved in a strongly clock-like manner. In addition,
significant temporal structure was observed using both a phylo-
genetic randomization test, in which MYXV sequences with
randomized times of sampling produced a distribution of
substitution rates significantly different to that observed in the
real MYXV data (Figure 1b), and in a regression analysis of root-
to-tip genetic distances against sampling times (Figure 1c; corre-
lation coefficient = 0.98, although this value will be inflated to
some extent by phylogenetic non-independence in the data). In
sum, there is measurable, and therefore relatively rapid, viral
evolution over the sampling period. Accordingly, those Australian
MYXV isolates sampled from the 1990s share a common ancestor
that existed between 1964–1971.
Evolution of MYXV virulence in Australia
Fenner and colleagues categorised virulence on a scale from
grade 1 (extreme lethality) to grade 5 (case fatality rate ,50%)
(Table 2). Nine of the 19 Australian MYXV isolates sequenced
here have been phenotyped for virulence (Figure 1a; Table 1).
These cover almost 50 years of viral evolution and the full range of
virulence, including viruses that are as lethal as the progenitor SLS
(grade 1) strain, as well as those with attenuated phenotypes and
prolonged survival times (grade 5). Three of the phenotyped
isolates were sampled during the initial epidemic; the Glenfield
strain (Dubbo, Feb. 1951; grade 1), KM13 (Corowa, Dec. 1952;
grade 3) and Uriarra (Feb. 1953; originally characterised as grade
4, but grade 5 in more recent testing [20]). Glenfield was more
virulent than SLS when tested in resistant rabbits demonstrating
that virulence can increase as well as decrease [21]. The remaining
six phenotyped MYXV viruses were isolated between 1991 and
1999: Bendigo, Wellington, BRK (grade 1), SWH, Gung (grade 4)
and Meby (grade 5) [22]. Among all nine phenotyped viruses there
were 109 nonsynonymous mutations and 18 insertion-deletions
(indels; ranging from 1–92 bp in length) in 67 open reading frames
compared to the ancestral SLS sequence (Table S1). Strikingly,
only two nonsynonymous (amino changes P76H in M140R and
L204S in M153R) and two synonymous mutations are shared by
all 19 Australian viruses compared to SLS. The genomic locations
of the mutations in all 19 Australian MYXV isolates are shown in
Figure 2. A total of 23 nonsynonymous, nine synonymous and one
intergenic mutation fall on the branch separating the Australian
viruses sampled during the 1990s from their 1950s relatives (Table
S1). Interestingly, two indels are also reconstructed to fall on the
branch separating the 1950s and 1990s Australian viruses; an A
insert in M009L which disrupts this ORF (and that reverts in
Bendigo), and a G insert in M083L that corrects a reading frame
disruption in SLS and the other early Australian viruses. As
Author Summary
The text-book example of the evolution of virulence is the
attenuation of myxoma virus (MYXV) following its intro-
duction as a biological control into the European rabbit
populations of Australia and Europe in the 1950s.
However, the key work on this topic, most notably by
Frank Fenner and his colleagues, occurred before the
availability of genome sequence data. The evolutionary
genetic basis to the major changes in virulence in both the
Australian and European epidemics is therefore largely
unknown. We provide, for the first time, key details on the
genome-wide changes that underpin this landmark exam-
ple of pathogen emergence and virulence evolution. By
sequencing and comparing MYXV genomes, including the
original strains released in the 1950s, we show that (i)
MYXV evolved rapidly in both Australia and Europe,
producing one of the highest rates of evolutionary change
ever recorded for a DNA virus, (ii) that changes in virulence
were caused by mutations in multiple genes, often
involving losses of gene function due to insertions and
deletions, and that (iii) strains of the same virulence were
defined by different mutations, such that both attenuated
and virulent MYXV strains are produced by a variety
genetic pathways, and generating convergent evolution
for phenotype but not genotype.
Evolution of Virulence in Myxoma Virus
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MYXV will have clearly been subject to a variety of selection
pressures over our sampling period, including adaptation to the
European rabbit following the species jump from the tapeti, it is
likely that only a subset of these mutations would be responsible
for virulence evolution.
Some mutations, and particularly indels, have a clear impact on
virulence. For example, the highly attenuated Uriarra strain
contains a C nucleotide insertion in M005L/R that disrupts the
reading frame. M005 is an E3 Ub ligase that manipulates cell cycle
progression and inhibits cell death; as it is known to be critical for
virulence, this indel is likely the main mutation responsible for the
attenuation of Uriarra [23,24]. The grade 5 Meby strain has a
73 bp deletion in the conserved region of M153R [22,25] which
leads to read-through of the normal stop codon and an altered C-
terminal protein sequence which is no longer highly acidic.
M153R is a key virulence gene [26], encoding an E3 Ub ligase
with an N-terminal RING-CH domain responsible for downreg-
ulation of MHC-1, CD4, ALCAM/CD166 and Fas/CD95 on the
membrane of infected cells [25–28]. Hence, this mutation is
predicted to impair the capacity of MYXV to interfere with host
destruction of infected cells, resulting in an attenuated phenotype.
Aside from these particular indels, the mutational events
responsible for other changes in virulence are less obvious. To
frame our analysis of virulence evolution, we consider the two
simplest hypotheses to account for this changing MYXV
phenotype in Australia. The most parsimonious explanation is
that the mutations that caused attenuation in the early 1950s were
maintained over the subsequent half century; hence, the pheno-
typic diversity in the 1990s was due to the co-circulation of
virulence determinants present in the ancestral strain and
attenuation mutations favoured by natural selection in the period
immediately after viral release (the ‘attenuation-only’ model). A
competing hypothesis is that the early MYXV strains fixed
mutations that resulted in an attenuated phenotype, and that the
Table 1. Strains of MYXV sequenced here and their origin (in Australia unless stated otherwise).
Virus Formal name (including year) Geographic origin Source Reference
Virulence
grade
Region
sequencedd
SLS (Moses strain/
strain B)
None given Brazil Rabbit tissue stock a(Fenner) [3] 1 1-161777 (161763)
Glenfield Aust/Dubbo/2-51/1 Central NSW bCV-1 cell stock [49] 1 15-161763 (161742)
KM13 Aust/Corowa/12-52/2 Southern NSW Rabbit tissue stock (Fenner) [3] 3 1-161777 (161771)
Uriarra Aust/Uriarra/2-53/1 Canberra district CV-1 cell stock [49] 5 1-161777 (161768)
SWH Aust/Southwell Hill/9-92/1 Canberra district Wild rabbit [22] 4 1-161777 (161797)
BRK Aust/Brooklands/4-93 Canberra district Wild rabbit [22] 1 1-161777 (161701)
Bendigo Aust/Bendigo/7-92 Central Victoria Wild rabbit [22] 1 1-161777 (161738)
Meby Aust/Meby/8-91 Tasmania Wild rabbit [22] 5 87-161691 (161542)
Lausanne Brazil/Campinas/1949/1 Brazil cCommonwealth Serum
Laboratories 1973
- 1 1-161777 (161778)
Cornwall England/Cornwall/4-54/1 Cornwall UK Rabbit tissue stock (Fenner) [3] 1 1-161777 (161775)
Nottingham
attenuated
England/Nottingham/4-55/1 Nottingham UK Rabbit tissue stock (Fenner) [3] 5 1-161777 (161777)
Gung Aust/Gungahlin/1-91 Canberra district Wild rabbit [22] 4 151-161627
(161443)
Wellington Aust/Wellington/1-91 Central NSW Wild rabbit [22] 1 29-161749 (161688)
BRK 12-2-93 Aust/Brooklands/2-93 Canberra district Wild rabbit [38] ND 140-161638
(161496)
BD23 Aust/Bulloo Downs/11-99 SW Queensland Wild rabbit [50] ND 285-161555
(161971)
BRK 897 Aust/Brooklands/1-95 Canberra district Wild rabbit [38] ND 103-161675
(161545)
OB1 406 Aust/OB1/Hall/3-94 Canberra district Wild rabbit [38] ND 87-161691 (161612)
WS1 234 Australia/Woodstock 1/3-94 Canberra district Wild rabbit [38] ND 1-161777 (161754)
WS6 1071 Aust/Woodstock 6/11-95 Canberra district Wild rabbit [38] ND 41-161737 (161752)
WS1 328 Aust/Woodstock 1/3-94 Canberra district Wild rabbit [38] ND 156-161622
(161483)
WS6 346 Aust/Woodstock 6/3-95 Canberra district Wild rabbit [38] ND 140-161638
(161430)
SWH 8-2-93 Aust/Southwell Hill/2-93 Canberra district Wild rabbit [38] ND 1-161777 (161740)
SWH 1209 Aust/Southwell Hill/2-96 Canberra district Wild rabbit [38] ND 33-161745 (162413)
aVirus stocks were originally obtained as freeze dried rabbit tissue from Prof. Frank Fenner, John Curtin School of Medical Research, Australian National University,
Canberra, Australia.
bVirus stocks were from viruses plaque purified as described previously [49].
cVirus was from an ampoule of freeze dried rabbit tissue powder prepared by the Commonwealth Serum Laboratories for rabbit control.
dBased on the Lu sequence from Cameron et al. [16] 1-161777 as corrected by Morales et al. [18]; the actual sequence length is shown in parenthesis.
doi:10.1371/journal.ppat.1002950.t001
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appearance of the highly virulent grade 1 viruses in the 1990s was
due to mutations which restored virulence. Under this ‘attenua-
tion-restoration’ model patterns of phenotypic evolution over the
half century following release would be due to changes in the
relative frequency of strains with ancestral virulence, attenuation
mutations that occurred soon after release, and strains with de novo
mutations that restored high virulence.
Under either scenario, our genomic data can account for the
observed pattern of virulence evolution only if phenotypic
convergence has been achieved through multiple genetic routes.
Attenuation is never associated with convergence at the genotypic
level: among coding mutations, none uniquely define our single
grade 3 virus, none are uniquely shared by both grade 4 viruses,
and none are uniquely shared by both grade 5 viruses (Table S1).
For example, the two grade 5 viruses, Meby and Uriarra, only
share those nonsynonymous mutations that are fixed in all
Australian strains, including those of high virulence. Similarly,
no mutations are uniquely shared by the three grade 1 viruses
isolated in the 1990s. Thus, if novel mutations did restore
virulence to these viruses, these are specific to each. A picture of
multiple genetic pathways is also observed at the genic level: none
of the virulence grades can be defined by uniquely mutated genes.
Although it is clear that there are multiple routes to
attenuation/virulence, mapping virulence grade on to our
phylogeny using a parsimony procedure (Figure 1a) results in
ambiguous state characteristics for most nodes, so that it
impossible to determine the exact direction of virulence evolution.
We note, however, that the ‘attenuation-only’ model cannot easily
account for the phenotype of KM13, a grade 3 virus recovered late
in 1952. Although KM13 differs from SLS at five amino acids, all
are also found in at least one grade 1 virus. In addition, KM13 falls
in a phylogenetic position that is directly ancestral to the grade 1
Figure 1. Evolutionary history of MYXV. A: Maximum likelihood (ML) phylogeny of 24 complete genome sequences of MYXV. Viruses are color-
coded according to virulence grade (defined in Table 1); grade 1 = red, grades 3–4= green, grade 5 =blue. The tree is rooted between the two oldest
strains in the collection – Lausanne (1949) and SLS (1950) – which were used to seed the European and Australian epidemics, respectively (marked by
asterisks). The same root position is obtained under the mid-point method and from the Maximum Clade Credibility (MCC) tree in BEAST [19]. All
horizontal branch lengths are drawn to a scale of nucleotide substitutions per site, and bootstrap values .70% are shown. B: rate of the nucleotide
substitution (range of 95% HPD values) for the real MYXV genomic data set (on right in red) compared to 20 sequence data sets in which the year of
sampling has been randomized among the taxa. Note that the lower 95% HPD value for the randomized data tends to a zero rate. C: regression of
root-to-tip genetic distances against year of sampling for the 24 complete genomes of MYXV and inferred from the ML phylogenetic tree. The
correlation coefficient is 0.98 and the slope of the line, which is an estimator of the mean substitution rate, is 1.061025 subs/site/year.
doi:10.1371/journal.ppat.1002950.g001
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strains sampled in the 1990s (Figure 1a), suggesting that there was
global fixation of at least some attenuating mutations as predicted
by the ‘attenuation-restoration’ model.
Evolution of MYXV in Europe
To further explore the evolution of MYXV we sequenced two
British strains that have been phenotyped for virulence. Cornwall
is a grade 1 virulence virus isolated in April 1954 soon after the
release of MYXV in Britain [3], while Nottingham attenuated
(Nott), a grade 5 virulence virus, was obtained from an infected
rabbit in April 1955 [3]. We compared these viruses to both the
parental Lu strain (Table S2) and to MYXV/6918, a more recent
grade 5 virus from Spain.
The most likely explanation for the profound attenuation of
Nott is the insertion of a TG dinucleotide inM150R which leads to
a premature stop codon after amino acid 196. M150R encodes an
inhibitor of NFkB, and a virus in which this gene is insertionally
inactivated is highly attenuated [29,30]. Thus, as with the M153
mutation in Meby, attenuation has apparently been achieved by
the virus reducing its capacity to manipulate host immunity. This
TG insertion is not present in any of the Australian viruses, and
although six of the phenotyped Australian strains share a single
substitution in this gene, they span the full virulence spectrum
(Table S1). Similarly, single nucleotide insertions in M135R and
M148R are the most likely cause of the attenuation of MYXV/
6918 [18], none of which are seen in the Australian viruses.
Hence, despite the parallel evolution of MYXV attenuation in
Australia and Europe, different mutations in different genes were
responsible for the reduction in virulence in both cases. Indeed, of
the 482 mutations in the MYXV phylogeny, only two occur in
parallel between the Australian and European epidemics. Both are
nonsynonymous – a A37V amino acid replacement in M003.1 and
a P173S replacement in M150 – but they are found in Australian
viruses spanning the virulence spectrum and occur on the long
branches separating the 1990s from the 1950s viruses.
Discussion
Despite their importance as agents of disease, far less is known
about the evolutionary dynamics of large DNA viruses than of
RNA viruses, and what research has been done often relies on the
assumption that the viruses in question have co-diverged with their
hosts over long periods of evolutionary time [31]. Our sampling of
49 years of MYXV evolution therefore enables a unique snap-shot
of the pace of viral evolution in real-time. Accordingly, our
genome scale data provides strong evidence for the rapid evolution
of MYXV in both Australia and Europe. The rate of nucleotide
substitution we estimate here (,161025 subs/site/year) is one of
the highest ever reported for a dsDNA virus, but similar to that
documented in another poxvirus – Variola (VARV) virus – the
agent of smallpox [32]. These rates are approximately three orders
of magnitude higher than those estimated in the dsDNA vertebrate
herpesviruses assuming virus-host co-divergence [33], and where
there is a marked lack of temporal structure in the short-term [32].
It is therefore possible that poxviruses are characterized by
relatively high background mutation rates, which may in part
explain the clock constancy. However, direct estimates of mutation
rate are only available for a limited number of dsDNA viruses,
with none from the Poxviridae [34]. Alternatively, as MYXV was
likely subject to strong selection for enhanced transmissibility and
a variety of other phenotypic traits during our sampling period, it
is possible that its substitution rate has been elevated by adaptive
evolution. Nonsynonymous mutations were commonplace in the
MYXV phylogeny, and particularly on the branch separating the
1990s Australian viruses from those sampled forty years earlier.
However, their frequency of occurrence (,55% of all mutations in
coding regions) is still compatible with a predominantly neutral
evolutionary process. Indeed, the small number of point mutations
in individual MYXV genes precluded an analysis of gene and site-
specific selection pressures.
These data are also notable in that they show that the
attenuation of the grade 1 virulence of SLS in Australia was
achieved by unique mutations affecting a variety of different genes.
This may be a consequence of the initially wide geographic spread
of MYXV which, in combination with population devastation and
seasonal population bottlenecks, would have caused regionally
successful virulence mutants to arise and be lost stochastically. As
rabbits subsequently evolved resistance, it seems likely that a
variety of virulence-restoring mutations would be locally selected
among attenuated strains to maintain relative transmissibility,
which was maximal for grade 4 phenotypes when measured
experimentally in non-resistant laboratory rabbits [2]. Such a
scenario is compatible with our MYXV phylogeny (Figure 1a) in
which relatively few mutations are fixed on internal nodes of the
tree, particularly during the 1950s, with more mutations located
on the branches leading to individual variants and indicative of
localized evolution.
More broadly, our genome scale analysis of MYXV evolution
on two continents reveals that there are multiple routes to viral
virulence or attenuation, of which we have likely sampled only a
small number. Hence, there is convergence for phenotype but not
genotype. It is likely that many of the mutational changes
associated with virulence have subtle effects and are subject to
complex, but as yet undefined, epistatic interactions. Such
complexity could in part reflect the evolutionary arms race
involving selection for resistance in rabbits and counter-selection
for virulence in the virus to maintain transmissibility and
competitiveness, and which led to the reversal of attenuating
mutations, mutations that compensate for attenuating mutations,
Table 2. Virulence grades of myxoma viruses.
Severity gradea 1 2 3b 4 5
Virulence very high high moderate low very low
Case fatality rate 99.5% 95–99% 70–95% 50–70% ,50%
Average survival time (days) #13 14–16 17–28 29–50 Not defined
Prototype strain(s) SLS; Lausanne Not defined KM13 Uriarra; Loiret Neuromyxoma; Nott attenuated
aModified from refs. 1 and 3. Virulence assays were conducted in laboratory rabbits, so that they are independent of the resistance levels of the wild rabbit as it evolved
in response to the strong selection imposed by the virus. Virulence grades were assigned based on case fatality rates, average survival time and symptomatology.
bGrade 3 viruses were sometimes divided into 3A (case mortality rate of 90–95%; AST of 17–22 days) and 3B (case fatality rate of 70–90%; AST of 23–29 days) [1].
doi:10.1371/journal.ppat.1002950.t002
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or those that increase virulence by novel pathways. Indeed, it is
striking that both highly virulent and highly attenuated viruses
appear to be successful at least under some local conditions,
although the BRK and Bendigo viruses that possessed grade 1
virulence in laboratory rabbits were of grade 4 and 5 virulence,
respectively, when tested in wild resistant rabbits [35], and the
progenitor SLS strain was also effectively a grade 5 virus in
resistant rabbits [36]. These laboratory tests were performed under
cage or pen conditions and it is likely that virulence would be
higher in the field due to a variety of biotic and abiotic stress
factors, and which may in part explain the apparent success of
attenuated viruses such as SWH or Gung. In transmission trials
using viruses of virulence grades 1, 3 and 5, rabbits that died
quickly following infection and those that survived infection were
Figure 2. Gene map of MYXV based on the Lausanne (Lu) genome sequence (GenBank accession, NC_001132). Open reading frames
and their direction of transcription are shown as arrows, and gene identities are also indicated. Light arrows above the sequence indicate the terminal
inverted repeats of 11577 bp at each end of the genome. Vertical lines show the location of mutations in the Australian isolates of MYXV compared
to the SLS progenitor strain that initiated the Australian epizootic of myxomatosis.
doi:10.1371/journal.ppat.1002950.g002
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both poor sources of viral transmission by fleas; most transmission
occurred from those rabbits that had prolonged survival times but
ultimately died [37]. Stress due to nutrition, cold, and other
diseases may have increased the effective virulence of a field strain
of MYXV in individual rabbits, thereby enhancing the transmis-
sion of attenuated viruses and decreasing the transmission of more
virulent strains. In the fragmented rabbit populations of today
which are still considerably reduced from those in 1950, it may be
that both local ecological conditions and virulence plasticity are
critical for virus success. Clearly, multiple genetic variants of
MYXV may appear in relatively small geographic areas, with the
predominant viral type shifting from year to year [38].
Although in vitro studies of virulence determinants in viruses are
commonplace, MYXV occupies a unique position in studies of
virulence evolution because this evolutionary process occurred in
natural populations and virulence was experimentally assayed in a
controlled and relevant common garden species (laboratory
rabbits of the same species as those infected in the wild). Our
comparative genome sequence data suggests that the large and
complex genome of MYXV provides the plasticity for multiple
routes to attenuation, and multiple and complex routes back to
virulence. Such genetic flexibility sits in contrast to RNA viruses
such as West Nile [39], influenza A [40], and HIV-1 [41–43], in
which it has been suggested that a limited number of mutations
may control virulence. Key differences between large dsDNA
viruses like MYXV and these RNA viruses are that the latter
possess a limited number of genes that commonly encode multiple
functions, and experience infrequent gene duplication and lateral
gene transfer, all of which will limit the number of viable
evolutionary pathways [44]. In light of such evolutionary
complexity, it will be necessary to employ a systematic reverse
genetic approach to precisely determine the contribution of
individual mutations to the virulence and attenuation of this
important model of disease emergence. More generally, the
complex relationship between genotype and phenotype observed
here suggests that it will often be difficult to predict the future
course of virulence evolution in emerging pathogens from
comprehensive genome sequence data.
Materials and Methods
Virus growth and DNA extraction
All virus isolates analyzed here, as well as their virulence, are
described in Table S1. Viruses were passaged twice in RK13 cells
to produce working stocks. Concentrated virions were prepared
from infected RK13 cells and DNA extracted as described
previously, with the exception that DNA was ethanol precipitated
rather than dialysed [22].
Sequencing and genome assembly
We obtained and assembled complete or almost complete
genome sequences for 23 isolates of MYXV using the Roche GS-
FLX sequencing platform. Whole genome shotgun libraries were
created for each sample by fragmenting the genomic DNA using a
nebulization technique. The genomic libraries were sequenced in
multiple runs on the GS-FLX using the Titanium chemistry and a
16-well gasket to separate each sample on the picotiter plate (PTP).
Approximately 50–60% of all the sequence reads generated
corresponded to host genomic DNA so that the majority of the
samples had to be sequenced twice leading to an average sequence
coverage of 306 (range of 11–60X). Sequence reads were
assembled into contigs using the comparative assembler
AMOScmp [45] which uses a reference genome (Lu; GenBank
accession NC_001132) as a guide for the assembly of related
genomes, as well as with gsMapper (Roche). We also re-sequenced
a Lu strain as a control of our sequencing quality. In general, the
assembly produced two virus contigs per genome; one at
,11,500 bp corresponding to the collapsed terminal inverted
repeats and another, at ,140,000 bp, corresponding to the core
portion of the genome. For some genomes lighter coverage of
various regions led to gaps, or suspect areas, that were closed by
targeted Sanger sequencing. All high-quality reported single
nucleotide polymorphisms (SNPs) were also confirmed by Sanger
sequencing. SeqMan Pro (Lasergene) was used to incorporate
these finishing reads into the larger assembly, followed by visual
confirmation of coverage. All sequence data generated here has
been submitted to GenBank and assigned accession numbers
JX565562–JX565584.
Evolutionary analysis
We first screened for recombination in the 24 complete genome
sequences of MYXV (alignment length of 163,538 bp) using the
RDP, GENECOV, BOOTSCAN programs available within the
RDP3 package [46]. As no recombination was observed, a
phylogenetic tree was then inferred using the maximum likelihood
(ML) method available in the PAUP* package [47], and
employing Tree Bisection and Reconnection (TBR) branch-
swapping. Because of the very small number of nucleotide
substitutions across the MYXV genome, such that any multiple
substitution will be very limited, we utilized the HKY85 model of
nucleotide substitution with default parameters. A bootstrap
resampling analysis (1000 replications) was used to determine
the support for key nodes. Finally, we employed a parsimony
protocol to reconstruct the nucleotide changes along each branch
of the ML tree, again utilizing the PAUP* package.
To infer rates of nucleotide substitution we employed the
Bayesian Markov Chain Monte Carlo (MCMC) method available
in the BEAST package [19]. This analysis employed both strict
(i.e. constant) and relaxed (uncorrelated lognormal) molecular
clocks and utilized the year of sampling of each viral isolate. We
again employed the HKY85 model of nucleotide substitution as
well as a Bayesian skyline coalescent prior. MCMC chains of 100
million generations (with 10% burn-in) were run multiple times
until convergence was achieved for all parameters. Statistical
uncertainty was reflected in values for the 95% Highest Probability
Density (HPD). To determine whether there was sufficient
temporal structure in the data to accurately infer evolutionary
rates, we randomized sampling times 20 times across the MYXV
alignment and repeated the BEAST analysis described above. In
addition, we plotted root-to-tip genetic distances determined from
the ML tree against year of sampling using the Path-O-Gen
program (http://tree.bio.ed.ac.uk/software/pathogen/). For this
analysis the ML tree is rooted between the oldest Lu and SLS
strains, and which is also the deepest split in both BEAST and
mid-point rooted trees.
For the BEAST analysis we used two possible dates for the SLS
sequence; although the first description of this virus was published
in 1911 [48], it was subjected to regular rabbit passage until 1950
when it was released into Australia. Therefore, the ‘correct’
evolutionary date for SLS falls at some point between 1911 and
1950. Although estimates of the rate of nucleotide substitution
were similar under both the 1911 (95% HPD=7.6–9.061026
subs/site/year; strict clock) and 1950 (95% HPD=8.3–
10.961026 subs/site/year; strict clock) dates, we based our
analysis on the 1950 date as it provided a better fit to a strict
molecular clock, both with respect to the coefficient of variation in
BEAST (values of 0.418–1.076 and 0.00008–0.388 for the 1911
and 1950 dates, respectively) and in the root-to-tip regression
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(correlation coefficient = 0.92 and 0.98 for the 1911 and 1950
dates, respectively). However, the uncertainty over the correct
evolutionary date for SLS does compromise estimates of when this
virus shared a common ancestor with Lu.
Supporting Information
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